Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex

  1. Kusters, Johannes ORCID logo
  2. Diergaarde, Brenda
  3. Ness, Andrew
  4. van der Loeff, Maarten F. S.
  5. Heijne, Janneke, C. M.
  6. Schroeder, Lea
  7. Hueniken, Katrina
  8. McKay, James D.
  9. Macfarlane, Gary J.
  10. Lagiou, Pagona
  11. Lagiou, Areti
  12. Polesel, Jerry ORCID logo
  13. Agudo, Antonio
  14. Alemany, Laia
  15. Ahrens, Wolfgang ORCID logo
  16. Healy, Claire M.
  17. Conway, David ORCID logo
  18. Robinson, Max
  19. Canova, Cristina
  20. Holcátová, Ivana
  21. Richiardi, Lorenzo
  22. Znaor, Ariana ORCID logo
  23. Pring, Miranda
  24. Thomas, Steve
  25. Hayes, D. Neil ORCID logo
  26. Liu, Geoffrey
  27. Hung, Rayjean ORCID logo
  28. Brennan, Paul ORCID logo
  29. Olshan, Andrew F.
  30. Virani, Shama
  31. Waterboer, Tim

Download
Kusters-et-al_2023_Diagnostic accuracy of HPV16.pdf 1,76MB
WeightNameValue
1000 Titel
  • Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex
1000 Autor/in
  1. Kusters, Johannes |
  2. Diergaarde, Brenda |
  3. Ness, Andrew |
  4. van der Loeff, Maarten F. S. |
  5. Heijne, Janneke, C. M. |
  6. Schroeder, Lea |
  7. Hueniken, Katrina |
  8. McKay, James D. |
  9. Macfarlane, Gary J. |
  10. Lagiou, Pagona |
  11. Lagiou, Areti |
  12. Polesel, Jerry |
  13. Agudo, Antonio |
  14. Alemany, Laia |
  15. Ahrens, Wolfgang |
  16. Healy, Claire M. |
  17. Conway, David |
  18. Robinson, Max |
  19. Canova, Cristina |
  20. Holcátová, Ivana |
  21. Richiardi, Lorenzo |
  22. Znaor, Ariana |
  23. Pring, Miranda |
  24. Thomas, Steve |
  25. Hayes, D. Neil |
  26. Liu, Geoffrey |
  27. Hung, Rayjean |
  28. Brennan, Paul |
  29. Olshan, Andrew F. |
  30. Virani, Shama |
  31. Waterboer, Tim |
1000 Erscheinungsjahr 2023
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-09-11
1000 Erschienen in
1000 Quellenangabe
  • 154(2):389-402
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1002/ijc.34710 |
1000 Ergänzendes Material
  • https://onlinelibrary.wiley.com/doi/10.1002/ijc.34710#support-information-section |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • A growing proportion of head and neck cancer (HNC), especially oropharyngeal cancer (OPC), is caused by human papillomavirus (HPV). There are several markers for HPV-driven HNC, one being HPV early antigen serology. We aimed to investigate the diagnostic accuracy of HPV serology and its performance across patient characteristics. Data from the VOYAGER consortium was used, which comprises five studies on HNC from North America and Europe. Diagnostic accuracy, that is, sensitivity, specificity, Cohen's kappa and correctly classified proportions of HPV16 E6 serology, was assessed for OPC and other HNC using p16INK4a immunohistochemistry (p16), HPV in situ hybridization (ISH) and HPV PCR as reference methods. Stratified analyses were performed for variables including age, sex, smoking and alcohol use, to test the robustness of diagnostic accuracy. A risk-factor analysis based on serology was conducted, comparing HPV-driven to non-HPV-driven OPC. Overall, HPV serology had a sensitivity of 86.8% (95% CI 85.1-88.3) and specificity of 91.2% (95% CI 88.6-93.4) for HPV-driven OPC using p16 as a reference method. In stratified analyses, diagnostic accuracy remained consistent across sex and different age groups. Sensitivity was lower for heavy smokers (77.7%), OPC without lymph node involvement (74.4%) and the ARCAGE study (66.7%), while specificity decreased for cases with <10 pack-years (72.1%). The risk-factor model included study, year of diagnosis, age, sex, BMI, alcohol use, pack-years, TNM-T and TNM-N stage. HPV serology is a robust biomarker for HPV-driven OPC, and its diagnostic accuracy is independent of age and sex. Future research is suggested on the influence of smoking on HPV antibody levels.
1000 Sacherschließung
lokal oropharyngeal cancer
lokal head and neck cancer
lokal human papillomavirus
lokal serology
lokal diagnostic accuracy
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-2509-1661|https://frl.publisso.de/adhoc/uri/RGllcmdhYXJkZSwgQnJlbmRh|https://frl.publisso.de/adhoc/uri/TmVzcywgQW5kcmV3|https://frl.publisso.de/adhoc/uri/dmFuIGRlciBMb2VmZiwgTWFhcnRlbiBGLiBTLg==|https://frl.publisso.de/adhoc/uri/SGVpam5lLCBKYW5uZWtlLCBDLiBNLg==|https://frl.publisso.de/adhoc/uri/U2Nocm9lZGVyLCBMZWE=|https://frl.publisso.de/adhoc/uri/SHVlbmlrZW4sIEthdHJpbmE=|https://frl.publisso.de/adhoc/uri/TWNLYXksIEphbWVzIEQu|https://frl.publisso.de/adhoc/uri/TWFjZmFybGFuZSwgR2FyeSBKLg==|https://frl.publisso.de/adhoc/uri/TGFnaW91LCBQYWdvbmE=|https://frl.publisso.de/adhoc/uri/TGFnaW91LCBBcmV0aQ==|https://orcid.org/0000-0001-9381-1520|https://frl.publisso.de/adhoc/uri/QWd1ZG8sIEFudG9uaW8=|https://frl.publisso.de/adhoc/uri/QWxlbWFueSwgTGFpYQ==|https://orcid.org/0000-0003-3777-570X|https://frl.publisso.de/adhoc/uri/SGVhbHksIENsYWlyZSBNLg==|https://orcid.org/0000-0001-7762-4063|https://frl.publisso.de/adhoc/uri/Um9iaW5zb24sIE1heA==|https://frl.publisso.de/adhoc/uri/Q2Fub3ZhLCBDcmlzdGluYQ==|https://frl.publisso.de/adhoc/uri/SG9sY8OhdG92w6EsIEl2YW5h|https://frl.publisso.de/adhoc/uri/UmljaGlhcmRpLCBMb3Jlbnpv|https://orcid.org/0000-0002-5849-4782|https://frl.publisso.de/adhoc/uri/UHJpbmcsIE1pcmFuZGE=|https://frl.publisso.de/adhoc/uri/VGhvbWFzLCBTdGV2ZQ==|https://orcid.org/0000-0001-6203-7771|https://frl.publisso.de/adhoc/uri/TGl1LCBHZW9mZnJleQ==|https://orcid.org/0000-0002-4486-7496|https://orcid.org/0000-0002-0518-8714|https://frl.publisso.de/adhoc/uri/T2xzaGFuLCBBbmRyZXcgRi4=|https://frl.publisso.de/adhoc/uri/VmlyYW5pLCBTaGFtYQ==|https://frl.publisso.de/adhoc/uri/V2F0ZXJib2VyLCBUaW0=
1000 Label
1000 Förderer
  1. National Institutes of Health |
  2. National Institute of Dental and Craniofacial Research |
  3. Fifth Framework Programme |
  4. Associazione Italiana per la Ricerca sul Cancro |
  5. Compagnia di San Paolo |
  6. FIRMS |
  7. Regione Piemonte |
  8. Università degli Studi di Padova |
  9. National Cancer Institute |
  10. National Institute for Health and Care Research |
  11. Above and Beyond |
  12. University Hospitals Bristol NHS Foundation Trust |
  13. Weston Research Capability Funding |
  14. Cancer Research UK |
  15. Canadian Cancer Society Research Institute |
  16. Princess Margaret Hospital Foundation |
1000 Fördernummer
  1. R01 DE025712; P50CA097190; P30CA047904
  2. -
  3. QLK1-2001-00182
  4. -
  5. -
  6. -
  7. -
  8. CPDA057222
  9. R01-CA90731
  10. RP-PG-0707-10034
  11. -
  12. -
  13. -
  14. C18281/A19169
  15. -
  16. -
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
  5. -
  6. -
  7. -
  8. -
  9. -
  10. -
  11. -
  12. -
  13. -
  14. Integrative Cancer Epidemiology Programme
  15. -
  16. Lusi Wong Programs
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Institutes of Health |
    1000 Förderprogramm -
    1000 Fördernummer R01 DE025712; P50CA097190; P30CA047904
  2. 1000 joinedFunding-child
    1000 Förderer National Institute of Dental and Craniofacial Research |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Fifth Framework Programme |
    1000 Förderprogramm -
    1000 Fördernummer QLK1-2001-00182
  4. 1000 joinedFunding-child
    1000 Förderer Associazione Italiana per la Ricerca sul Cancro |
    1000 Förderprogramm -
    1000 Fördernummer -
  5. 1000 joinedFunding-child
    1000 Förderer Compagnia di San Paolo |
    1000 Förderprogramm -
    1000 Fördernummer -
  6. 1000 joinedFunding-child
    1000 Förderer FIRMS |
    1000 Förderprogramm -
    1000 Fördernummer -
  7. 1000 joinedFunding-child
    1000 Förderer Regione Piemonte |
    1000 Förderprogramm -
    1000 Fördernummer -
  8. 1000 joinedFunding-child
    1000 Förderer Università degli Studi di Padova |
    1000 Förderprogramm -
    1000 Fördernummer CPDA057222
  9. 1000 joinedFunding-child
    1000 Förderer National Cancer Institute |
    1000 Förderprogramm -
    1000 Fördernummer R01-CA90731
  10. 1000 joinedFunding-child
    1000 Förderer National Institute for Health and Care Research |
    1000 Förderprogramm -
    1000 Fördernummer RP-PG-0707-10034
  11. 1000 joinedFunding-child
    1000 Förderer Above and Beyond |
    1000 Förderprogramm -
    1000 Fördernummer -
  12. 1000 joinedFunding-child
    1000 Förderer University Hospitals Bristol NHS Foundation Trust |
    1000 Förderprogramm -
    1000 Fördernummer -
  13. 1000 joinedFunding-child
    1000 Förderer Weston Research Capability Funding |
    1000 Förderprogramm -
    1000 Fördernummer -
  14. 1000 joinedFunding-child
    1000 Förderer Cancer Research UK |
    1000 Förderprogramm Integrative Cancer Epidemiology Programme
    1000 Fördernummer C18281/A19169
  15. 1000 joinedFunding-child
    1000 Förderer Canadian Cancer Society Research Institute |
    1000 Förderprogramm -
    1000 Fördernummer -
  16. 1000 joinedFunding-child
    1000 Förderer Princess Margaret Hospital Foundation |
    1000 Förderprogramm Lusi Wong Programs
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6473107.rdf
1000 Erstellt am 2024-02-06T12:41:46.724+0100
1000 Erstellt von 266
1000 beschreibt frl:6473107
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet Thu Feb 29 11:15:08 CET 2024
1000 Objekt bearb. Thu Feb 29 11:14:48 CET 2024
1000 Vgl. frl:6473107
1000 Oai Id
  1. oai:frl.publisso.de:frl:6473107 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source